Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 7/20 | 0.74 |
| ▸ | PARP15 | Q460N3 | 6/20 | 0.74 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.67 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.50 |
| ▸ | FNTA | P49354 | 1/20 | 0.49 |
| ▸ | FNTB | P49356 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.48 |
| ▸ | CDK2 | P24941 | 1/20 | 0.48 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12420700 | 1.00 | PARP10 (0.74) | PARP10PARP15PARP2NR1H4FFAR1 | |
| SCHEMBL1532862 | 1.00 | PARP10 (0.74) | PARP10PARP15PARP2NR1H4FFAR1 | |
| SCHEMBL12420703 | 0.98 | PARP10 (0.73) | PARP10PARP15PARP2NR1H4FFAR1 | |
| SCHEMBL2885506 | 0.95 | PARP10 (0.73) | PARP10PARP15PARP2NR1H4FFAR1 | |
| SCHEMBL416244 | 0.91 | PARP15 (0.72) | PARP10PARP15PARP2NR1H4PKM | |
| SCHEMBL6958286 | 0.85 | PARP10 (0.72) | PARP10PARP15PARP2FFAR1KMT2A | |
| SCHEMBL8016856 | 0.84 | PARP15 (0.62) | PARP10PARP15PARP2NR1H4PKM | |
| SCHEMBL10932224 | 0.84 | PARP10 (0.70) | PARP10PARP15PARP2FFAR1ALDH1A1 | |
| SCHEMBL12420708 | 0.84 | PARP15 (0.58) | PARP10PARP15PARP2NR1H4KMT2A | |
| SCHEMBL4688420 | 0.84 | TDP1 (0.60) | PARP10PARP15PARP2NR1H4PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111995567-B | Formamide pyridone iron chelator derivative with potential multi-target anti-AD activity and preparation method and application thereof | 浙江工业大学 | 2022-11-25 | — | — | CN | disclosed |
| CN-111995567-A | Formamide pyridone iron chelator derivative with potential multi-target anti-AD activity and preparation method and application thereof | 浙江工业大学 | 2020-11-27 | — | — | CN | disclosed |
| EP-2129218-B1 | COMPOUNDS HAVING A CYCLIC MOIETY AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECH INC (US) | 2016-10-19 | — | — | EP | disclosed |
| EP-2607362-B1 | Piperidine and piperazine carboxylates as FAAH inhibitors | ASTELLAS PHARMA INC (JP) | 2014-12-31 | — | — | EP | disclosed |
| EP-1849773-B1 | Piperazine derivatives for the treatment of urinary incontinence and pain | ASTELLAS PHARMA INC (JP) | 2013-10-16 | — | — | EP | disclosed |
| EP-2607362-A1 | Piperidine and piperazine carboxylates as FAAH inhibitors | Astellas Pharma Inc. (JP) | 2013-06-26 | — | — | EP | disclosed |
| US-8383852-B2 | Compounds having a cyclic moiety and compositions for delivering active agents | EMISPHERE TECHNOLOGIES, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-8383852-B2 | Compounds having a cyclic moiety and compositions for delivering active agents | EMISPHERE TECHNOLOGIES, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-07-14 | — | — | US | disclosed |
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-07-14 | — | — | US | disclosed |
| EP-1828177-A2 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006066173-A2 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2006-06-22 | — | — | WO | disclosed |
| EP-0777471-B1 | INHIBITION OF LEUKOTRIENE BIOSYNTHESIS WITH UREA DERIVATIVES | MINNESOTA MINING & MFG (US) | 2002-11-27 | — | — | EP | disclosed |
| EP-0927035-A4 | THROMBIN INHIBITORS | MERCK & CO INC (US) | 2002-11-13 | — | — | EP | disclosed |
| EP-0927035-A1 | THROMBIN INHIBITORS | Merck & Co., Inc. (US) | 1999-07-07 | — | — | EP | disclosed |
| US-5872138-A | INHIBITING LOSS OF BLOOD PLATELETS, INHIBITING FORMATION OF BLOOD PLATELET AGGREGATES, INHIBITING FORMATION OF FIBRIN, INHIBITING THROMBUS FORMATION, AND INHIBITING EMBOLUS FORMATION IN A MAMMAL | MERCK & CO., INC. (US) | 1999-02-16 | — | — | US | disclosed |
| WO-1998010763-A1 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 1998-03-19 | — | — | WO | disclosed |
| EP-0777471-A1 | INHIBITION OF LEUKOTRIENE BIOSYNTHESIS WITH UREA DERIVATIVES | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1997-06-11 | — | — | EP | disclosed |
| US-5612377-A | OXYUREA DERIVATIVE | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1997-03-18 | — | — | US | disclosed |
| WO-1996003983-A1 | INHIBITION OF LEUKOTRIENE BIOSYNTHESIS WITH UREA DERIVATIVES | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1996-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | FAAH, FAAH2, UTS2R | PARP10 2889/4885PARP15 2099/4885PARP2 2872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.